CpG-MCL

CpG-MCL is a patient-specific, autologous whole tumor cell vaccine developed for the treatment of mantle cell lymphoma (MCL). The vaccine is created by isolating malignant cells from each patient and activating them ex vivo with synthetic CpG oligodeoxynucleotides. This activation upregulates antigen-presenting and co-stimulatory molecules (such as MHC class I/II, CD80, CD86), enhancing the immunogenicity of the tumor cells. The resulting product is administered to patients as a personalized cancer vaccine to stimulate anti-tumor T-cell responses. In clinical trials, this approach has been combined with autologous stem cell transplantation and reinfusion of vaccine-primed T cells ("immunotransplant") in newly diagnosed adult MCL patients. The primary goal is to achieve freedom from minimal residual disease post-transplant by boosting anti-tumor immunity[6][8].

Other names

CpG-activated whole autologous tumor cell vaccine for mantle cell lymphomaCpG-MCL vaccine